In addition, Prieto-Alhambra et al. concluded that a target concentration of 40 ng/mL VD may prevent the development of aromatase-induced arthralgia, but higher loading doses are required to attain this level in women with a deficiency at baseline [43]. This evidence concerns the gene CYP19A1 and Arthralgia.